SunRock Biopharma

Captura-de-pantalla-41-1146x184
http://www.sunrockbiopharma.com/index.php?lang=en

 

CIMUS (Santiago de Compostela)

SunRock Biopharma is developing therapeutic antibodies against Chemokine Receptor 9 (CCR9).

CCR9 is a novel target, whose overexpression correlates with invasiveness of T Cell Acute Lymphocytic Leukaemia and solid tumors, such as ovarian, prostate, breast and melanoma.